Published in Cancer Weekly, February 22nd, 2000
"IFN-(alpha) or CD80 transduction of tumor cells individually reduces tumorigenicity and enhances antitumor responses," stated K. Hiroishi and colleagues from the University of Pittsburgh, Pennsylvania. "Here, we report that the combination of IFN-alpha and CD80 cancer gene therapy in poorly immunogenic murine tumor models, the colorectal adenocarcinoma cell line MC38, and the methylcholanthrene-induced fibrosarcoma cell line MCA205, reduces tumor growth...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.